Publications
19/08/2009
Two posters on EP42675 were published at ISTH Congress in Boston
Two posters on Endotis' EP42675 anticoagulant were published at the XXII congress of the International Society of Thrombosis and Haemostasis held in Boston in July 2009.
"Anticoagulant Activities of EP42675 - Synthetic Direct Inhibitor and Indirect Factor Xa Inhibitor", C. Bal dit Sollier et al.
"Pharmacokinetics and Pharmacodynamics of EP42675 a new synthetic anticoagulant with a dual mechanism of action", P. Gueret et al.
Two posters on Endotis' EP42675 anticoagulant were published at the XXII congress of the International Society of Thrombosis and Haemostasis held in Boston in July 2009.
"Anticoagulant Activities of EP42675 - Synthetic Direct Inhibitor and Indirect Factor Xa Inhibitor", C. Bal dit Sollier et al.
"Pharmacokinetics and Pharmacodynamics of EP42675 a new synthetic anticoagulant with a dual mechanism of action", P. Gueret et al.
08/04/2009
Endotis presents "Heparan Sulfate Mimetics as anticancer "small-glyco drugs" at 67th Harden Conference in Cambrigdge, UK
Heparan sulfate proteoglycans (HSPG) are involved in many of the physiopathological steps of tumour development. Through their interaction with target proteins which regulate cell proliferation, migration, adhesion and invasion, they play a crucial role in tumour angiogenesis and metastasis.
Endotis' platform for the development of anticancer small-glyco drugs aims to identify fully synthetic HS-mimetic oligosaccharides with potent affinity and selective inhibition of several growth factors and proteins (VEGF-A, FGF-2, PDGF-B, SDF-1a, heparanase...) involved in tumour growth and dissemination. We have synthesized a library of over 100 synthetic oligosaccharides of different sizes containing various
substituents and evaluated their affinity for the corresponding targets and their efficacy on cell proliferation and migration and in vitro endothelial tubule formation. Our data indicate that affinity and selectivity of HS-mimetics for the different targets can be finely tuned according to chemical substitutions.
Heparan sulfate proteoglycans (HSPG) are involved in many of the physiopathological steps of tumour development. Through their interaction with target proteins which regulate cell proliferation, migration, adhesion and invasion, they play a crucial role in tumour angiogenesis and metastasis.
Endotis' platform for the development of anticancer small-glyco drugs aims to identify fully synthetic HS-mimetic oligosaccharides with potent affinity and selective inhibition of several growth factors and proteins (VEGF-A, FGF-2, PDGF-B, SDF-1a, heparanase...) involved in tumour growth and dissemination. We have synthesized a library of over 100 synthetic oligosaccharides of different sizes containing various
substituents and evaluated their affinity for the corresponding targets and their efficacy on cell proliferation and migration and in vitro endothelial tubule formation. Our data indicate that affinity and selectivity of HS-mimetics for the different targets can be finely tuned according to chemical substitutions.